Want to see AAPG full AI Analyst Report?
Ascentage Pharma Group International Unsponsored ADR (AAPG) AI Stock Analysis
Ascentage Pharma Group International Unsponsored ADR
(NASDAQ:AAPG)
The score is held back primarily by weak financial performance (large and worsening losses plus accelerating cash burn) and a weak technical trend (below key moving averages with negative MACD). These are partially offset by a positive earnings call centered on runway visibility through 2027, revenue growth, and meaningful clinical/regulatory progress that could drive future catalysts.
Ascentage Pharma Group International Unsponsored ADR (AAPG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.26B
- Dividend Yield
- ―
- Average Volume (3M)
- 7,052
- Price to Earnings (P/E)
- -5.9
- Beta (1Y)
- 0.90
- Revenue Growth
- 69.80%
- EPS Growth
- -12.46%
- Country
- US
- Employees
- 767
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Ascentage Pharma Group International Unsponsored ADR Business Overview & Revenue Model
Company Description
Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, inclu...
How the Company Makes Money
Public, company-specific detail for AAPG (an unsponsored ADR) regarding Ascentage Pharma Group International’s revenue breakdown, exact commercial products, and partnership terms is null in the available context. In general, biopharmaceutical compani...
Ascentage Pharma Group International Unsponsored ADR Earnings Call Summary
Overall the call conveyed substantial positive progress: meaningful revenue growth (+29.3% YoY), solid product sales contribution ($41.6M), a strong cash balance ($279.4M) and clear clinical/regulatory momentum with multiple FDA/EMA-cleared global registrational trials and promising efficacy/safety data for core assets (lisaftoclax and olverembatinib). The company reinforced commercialization capabilities with senior hires and a Takeda option for global rights to olverembatinib. Offsetting risks include rapidly rising R&D and commercial spending (R&D +32%, S&D +64.3% YoY), limited runway visibility beyond end-2027 without further funding or partner actions, competitive pressures in key therapeutic classes, and some early-stage programs that require more data. On balance, the positives — regulatory progress, strong clinical signals, revenue growth and strategic partnerships — outweigh the near-term financial and competitive risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reaffirmed a cash runway through the end of 2027 with $279.4 million in cash as of June 30, 2026 to fund nine global registrational programs (four cleared by FDA/EMA) and seven active clinical assets (two approved); H1 revenue was $44.5M (up ~29% YoY from $32.6M) with product sales of $41.6M, while H1 operating spend included R&D $102.8M (vs $73.8M, +$29M/+32%), selling & distribution $33.4M (vs $19.2M, +$14.2M/+64.3%) and admin $17.5M (vs $13.9M). Enrollment updates: GLORA-2 is complete, GLORA-3 is near complete, and GLORA-4 plus POLARIS‑1/2 are expected to finish enrollment late this year/early next year (POLARIS‑2 total ~333 patients with a 48‑patient Part B), putting the company on track to pursue as many as three NDA filings in the second half of next year; commercial execution goals include expanding the China commercial team from ~300 toward ~400 to cover ~2,000 hospitals.
Ascentage Pharma Group International Unsponsored ADR Financial Statement Overview
Summary
Strong revenue growth and very high gross margins are outweighed by sharply widening operating losses and heavy, accelerating cash burn (deeply negative operating and free cash flow), keeping external funding risk elevated despite improved leverage versus 2023.
Income Statement
24NegativeBalance Sheet
38NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 633.01M | 558.48M | 980.65M | 221.98M | 209.71M | 27.91M |
| Gross Profit | 516.31M | 426.75M | 951.57M | 191.44M | 187.71M | 24.58M |
| EBITDA | -1.30B | -1.09B | -237.63M | -743.61M | -771.47M | -787.19M |
| Net Income | -1.45B | -1.21B | -405.43M | -925.64M | -882.92M | -782.42M |
Balance Sheet | ||||||
| Total Assets | 3.24B | 3.97B | 2.62B | 2.50B | 2.83B | 2.94B |
| Cash, Cash Equivalents and Short-Term Investments | 1.90B | 2.47B | 1.24B | 1.07B | 1.48B | 1.71B |
| Total Debt | 2.10B | 1.98B | 1.67B | 1.80B | 1.79B | 1.08B |
| Total Liabilities | 2.68B | 2.63B | 2.34B | 2.43B | 2.42B | 1.71B |
| Stockholders Equity | 556.58M | 1.33B | 264.19M | 60.42M | 408.66M | 1.23B |
Cash Flow | ||||||
| Free Cash Flow | -1.40B | -1.20B | -135.65M | -782.92M | -890.88M | -1.04B |
| Operating Cash Flow | -1.38B | -1.17B | -111.36M | -726.08M | -653.91M | -604.68M |
| Investing Cash Flow | 617.65M | -1.00B | -362.04M | 21.92M | -384.61M | -466.52M |
| Financing Cash Flow | 1.70B | 2.54B | 314.77M | 368.75M | 619.27M | 1.78B |
Ascentage Pharma Group International Unsponsored ADR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AAPG, the sentiment is Negative. The current price of 13.60 is below the 20-day moving average (MA) of 15.09, below the 50-day MA of 15.80, and below the 200-day MA of 20.08, indicating a bearish trend. The MACD of -0.36 indicates Positive momentum. The RSI at 36.44 is Neutral, neither overbought nor oversold. The STOCH value of 12.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AAPG.
Ascentage Pharma Group International Unsponsored ADR Peers Comparison
Overall Rating
ZYME59Neutral
KURA57.7Neutral
IMCR54Neutral- AAPG53Neutral
XNCR47.4Neutral
ORIC44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ZYME | 59Neutral | $2.03B | -14.35 | -72.07% | ― | -69.78% | -106.07% |
| KURA | 58Neutral | $912.74M | -2.90 | -207.18% | ― | -7.27% | -48.89% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IMCR | 54Neutral | $1.57B | -165.22 | -2.35% | ― | 20.19% | ― |
| AAPG | 53Neutral | $1.29B | -5.86 | -153.78% | ― | 69.80% | -12.46% |
| XNCR | 47Neutral | $2.22B | -13.67 | -28.66% | ― | -28.56% | 10.25% |
| ORIC | 44Neutral | $957.75M | -6.72 | -35.35% | ― | ― | 28.64% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AAPG | Ascentage Pharma Group International Unsponsored ADR | 13.56 | -19.69 | -59.22% | |
| XNCR | Xencor Inc. | 29.66 | 15.96 | 116.50% | |
| KURA | Kura Oncology | 9.79 | -0.17 | -1.71% | |
| ZYME | Zymeworks | 28.99 | 10.83 | 59.64% | |
| ORIC | Oric Pharmaceuticals Inc | 9.07 | -3.23 | -26.26% | |
| IMCR | Immunocore Holdings Plc | 29.79 | -2.12 | -6.64% |
Ascentage Pharma Group International Unsponsored ADR Corporate Events
Ascentage Pharma Corrects Timing for August 19, 2026 Interim Results Webcast
On August 5, 2026, Ascentage Pharma Group International issued a corrected announcement stating it will report unaudited six-month 2026 interim results and provide a corporate update via webcast at 7:00 a.m. Eastern Daylight Time and 7:00 p.m. Hong K...
Ascentage Pharma CEO Dajun Yang Ranked Among Top Small-Molecule Leaders in 2026 Power List
On July 26, 2026, Ascentage Pharma announced that its co-founder, Chairman and CEO Dr. Dajun Yang was ranked No. 3 in the Small Molecules category of The Medicine Maker Power List 2026, an annual global ranking of 60 leaders across drug discovery, ma...
Ascentage Pharma Sets Up US$200 Million Nasdaq ATM Offering Following SEC Shelf Filing
On July 20, 2026, Ascentage Pharma Group International announced that it had filed an automatic shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission as a well-known seasoned issuer, enabling future offerings of Am...
Ascentage Pharma Corrects AGM Date Underpinning Equity Incentive Mandate
Ascentage Pharma Group International, a Hong Kong–listed biopharmaceutical company incorporated in the Cayman Islands and based in Suzhou, China, develops innovative cancer and related therapies while operating under a board structure that incl...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 07, 2026